ICU: QUELIMMUNE sales surged as adult AKI trial enrollment advanced to 251 patients

SeaStar Medical (ICU) reported Q3 revenue of $635K, up 247% YoY, with gross margins above 90%. Net loss widened to $4.529M. The NEUTRALIZE-AKI trial enrolled 251 of 339 patients, and the first PMA module was submitted to the FDA.

Original reporting
Published Nov 11, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ICU: QUELIMMUNE sales surged as adult AKI trial enrollment advanced to 251 patients — source image
Decision brief

The 30-second read

$ICUBullishMed
01

Why it matters

The disclosed revenue surge and trial enrollment progress provide fresh material for traders evaluating the stock's upside potential.

02

Market read

New financial and clinical data could trigger a short‑term price rally.

03

What to watch

The company still reports a widening net loss, which may temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: on filing today

Background

SeaStar Medical Holding Corp (ICU) filed an 8‑K reporting Q3 results and clinical trial milestones.

Company-level read

Ticker impact

$ICUBullishHigh confidence
Context

Q3 revenue rose 247% YoY to $635K and trial enrollment reached 251 patients, with a PMA module submitted to the FDA.

Expected impact

likely upward pressure as investors price in the chance of FDA clearance and higher sales.

Evidence & confidence

Clinical progress and a filing for a PMA are material catalysts for a biotech micro‑cap, often driving share price gains.

Market effects

Positive signal for the renal‑failure biotech sector, may lift peer valuations.

US biotech market sees modest uplift.

Limited to investors tracking niche AKI therapeutics.

Counterpoint

If the FDA requires additional data, the current optimism could reverse quickly.

Key entities

  • SeaStar Medical Holding Corp

    US‑listed biotech focused on acute kidney injury treatments.

Related articles

$ICUHigh

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p